Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Operating Expenses (2016 - 2025)

Guided Therapeutics' Operating Expenses history spans 15 years, with the latest figure at $520000.0 for Q3 2025.

  • For Q3 2025, Operating Expenses fell 7.31% year-over-year to $520000.0; the TTM value through Sep 2025 reached $2.3 million, up 10.86%, while the annual FY2024 figure was $2.1 million, 39.59% down from the prior year.
  • Operating Expenses for Q3 2025 was $520000.0 at Guided Therapeutics, down from $841000.0 in the prior quarter.
  • Across five years, Operating Expenses topped out at $1.5 million in Q2 2023 and bottomed at $363000.0 in Q1 2024.
  • The 5-year median for Operating Expenses is $563000.0 (2021), against an average of $682631.6.
  • The largest annual shift saw Operating Expenses soared 240.08% in 2021 before it tumbled 57.59% in 2024.
  • A 5-year view of Operating Expenses shows it stood at $476000.0 in 2021, then surged by 82.77% to $870000.0 in 2022, then plummeted by 42.3% to $502000.0 in 2023, then rose by 5.98% to $532000.0 in 2024, then dropped by 2.26% to $520000.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Operating Expenses are $520000.0 (Q3 2025), $841000.0 (Q2 2025), and $414000.0 (Q1 2025).